BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 66
- Registration Number
- NCT04436107
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Conditions
- Hepatocellular CarcinomaUnresectable Hepatocellular CarcinomaMetastatic Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 64
- Registration Number
- NCT04401800
- Locations
- 🇨🇳
Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, China
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
- Conditions
- COVID-19COVID-19 Pulmonary Complications
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 63
- Registration Number
- NCT04382586
- Locations
- 🇺🇸
St Jude Medical Center, Fullerton, California, United States
🇺🇸Medstar Heath Research Institute Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸John D Archbold Memorial Hospital, Thomasville, Georgia, United States
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 453
- Registration Number
- NCT04379635
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Quanzhou First Affliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 46
- Registration Number
- NCT04318080
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaFollicular LymphomaMarginal Zone LymphomaMantle Cell LymphomaDiffuse Large B Cell LymphomaAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 97
- Registration Number
- NCT04282018
- Locations
- 🇦🇺
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇦🇺Saint Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
- Conditions
- Mature B-Cell Malignancies
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 437
- Registration Number
- NCT04277637
- Locations
- 🇺🇸
UCLA Hematologyoncology, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
- Conditions
- Breast CancerGastric CancerGastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 71
- Registration Number
- NCT04276493
- Locations
- 🇨🇳
The Third Hospital of Nanchang, Nanchang, Jiangxi, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorNasopharyngeal Carcinoma (NPC)Non Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 204
- Registration Number
- NCT04215978
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence (cCARE), San Diego, California, United States
🇺🇸UPMC Hillman Cancer Center (Univ Of Pittsburgh), Pittsburgh, Pennsylvania, United States
🇦🇺Blacktown Cancer And Haematology Centre, Blacktown, New South Wales, Australia
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 55
- Registration Number
- NCT04172246
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵Toyohashi Municipal Hospital, Toyohashishi, Aichi, Japan
🇯🇵Chiba Cancer Center, Chibashi, Chiba, Japan